HROW — HARROW, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1360214 ·
Last close
$30.52
Market Cap
$1.14B
52W High
$54.85
52W Low
$28.54
ADV30
549,994
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 70,661,000 | 50,363,000 | -11,007,000 | -17,270,000 | 416,816,000 | 83,889,000 | 401,971,000 |
| Mar 2026 | 44,203,000 | 27,045,000 | -22,080,000 | -27,602,000 | 419,543,000 | 94,644,000 | 391,192,000 |
| Dec 2025 | 89,092,000 | 70,624,000 | 15,591,000 | 6,626,000 | 399,482,000 | 72,927,000 | 347,391,000 |
| Sep 2025 | 71,638,000 | 53,926,000 | 14,747,000 | 1,020,000 | 363,074,000 | 74,290,000 | 316,413,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,204,000
Investing CF
$-23,451,000
Financing CF
$36,165,000
CapEx
$-19,093,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-184,126,000
Inventory
$16,496,000
Receivables
$101,259,000
ST Investments
$0
EBIT TTM
$11,964,000
Pretax Income TTM
$-11,165,000
Interest Exp TTM
$23,129,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$275,593,984
EBITDA
$17,715,000
Free Cash Flow
$-5,490,125
Enterprise Value
$1,507,653,120
Total Cash
$85,317,000
Total Debt
$300,744,000
Shares Out
37,487,850
Trailing EPS
$-0.99
Book Value
$0.41
ROE
-116.1%
ROA
-0.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 272,303,000 | 30,515,000 | -5,139,000 | 399,482,000 | 347,391,000 | 52,446,000 | 43,864,000 |
| Dec 2024 | 199,614,000 | 9,075,000 | -17,481,000 | 388,971,000 | 319,674,000 | 69,652,000 | -22,202,000 |
| Dec 2023 | 130,193,000 | 811,000 | -24,411,000 | 312,164,000 | 241,753,000 | 70,766,000 | 3,840,000 |
| Dec 2022 | 88,595,000 | 1,919,000 | -14,086,000 | 157,378,000 | 130,138,000 | 27,595,000 | 1,705,000 |
TTM Snapshot
Revenues TTM
$268,675,000
NetIncome TTM
$-14,961,000
OpCashFlow TTM
—
Assets (Latest)
$419,543,000
Forward EPS
$2.83
Max Pain — expiry 2027-01-15
max pain strike: $28.00 · spot: $29.36 · call oi: 31,005 · put oi: 4,272
Expected Move to 2027-01-15:
±$13.96
(47.55%) —
implied range
$15.40 –
$43.32
· ATM straddle on $29.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | $1.14B | $32.01 | — |
| BCAX | Bicara Therapeutics Inc. | $1.14B | $17.26 | — |
| AVLN | Avalyn Pharma Inc. | $1.14B | $25.72 | — |
| JANX | Janux Therapeutics, Inc. | $1.13B | $18.50 | — |
| NBTX | Nanobiotix S.A. | $1.16B | $22.90 | — |
News headlines (Yahoo Finance, 1h cache)
Do Options Traders Know Something About Harrow Stock We Don't?
2026-10-09 11:46 · Yahoo
Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?
2026-10-08 01:15 · Yahoo
Harrow to Participate in Three Investor Conferences in September
2026-09-01 11:00 · Yahoo
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
2026-08-20 12:24 · Yahoo
Harrow (HROW) Q2 2026 Earnings Call Transcript
2026-08-17 23:43 · Yahoo
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
2026-08-13 23:03 · Yahoo
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition
2026-08-12 09:10 · Yahoo
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ...
2026-08-11 19:01 · Yahoo
Harrow Closes Acquisition of TYRVAYA®
2026-10-05 11:00 · Yahoo
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
2026-08-20 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.